About: SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 18 July 2017

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2017 (fr) наукова стаття, опублікована в липні 2017 (uk) im Juli 2017 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 18 July 2017 (en) artículu científicu espublizáu en xunetu de 2017 (ast)
publication date	wds:Q88579083-11BCD745-F4FB-4A20-B19A-A45DB1CFFAEB
publication date	2017-07-18 00:00:00Z (xsd:dateTime)
cites work	wds:Q88579083-796A95CE-1777-4948-9A76-811176558804 wds:Q88579083-7E620A0C-22D4-40E8-95B4-EF422E75984F wds:Q88579083-B57B14C9-39C9-4344-AD8D-1BE1631A5E48 wds:Q88579083-EE108D9D-8F57-4E84-AA15-4D16705C5FD1
cites work	Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
author name string	wds:Q88579083-3DF95957-EF03-4621-8854-FE45C769C3C3
author name string	Gian Paolo Fadini
rdfs:label	SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System (en) SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System (nl)
skos:prefLabel	SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System (en) SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System (nl)
name	SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System (en) SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System (nl)
author	wds:Q88579083-EA0A8DED-75A7-479B-AA9F-B177299F99C2
author	Angelo Avogaro
title	wds:Q88579083-8AE84501-4F6C-4599-9CE8-1E792388696B
title	SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System (en)
page(s)	wds:Q88579083-18855458-1DC0-4262-B982-70755F38566D
page(s)	680-681
instance of	wds:Q88579083-9B4F8975-EC86-44FC-844C-7788391F55F1
instance of	scholarly article
main subject	wds:Q88579083-EBCF5847-D107-48EF-9481-EF87213BECDA
main subject	United States of America
PubMed ID	wds:Q88579083-65C3582F-65C3-4C6F-9D81-E78B3F29AB47
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/28733172
PubMed ID	28733172
published in	wds:Q88579083-1753F7C6-565F-4D8B-AB66-3CE9A821832F
published in	The Lancet: Diabetes & Endocrinology
issue	wds:Q88579083-DC16175E-B723-4F9C-B642-B441A620C086
volume	wds:Q88579083-5D947156-8247-4476-8524-A94357852651
issue	9
volume	5
DOI	wds:Q88579083-3D9D9989-8CE0-4EBF-B6EE-F0DD1201BB25
DOI	http://dx.doi.org/10.1016/S2213-8587(17)30257-7
DOI	10.1016/S2213-8587(17)30257-7
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q88579083
is cites work of	Canagliflozin: A Review in Type 2 Diabetes Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit? Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real W Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Updates on cardiovascular outcome trials in diabetes Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments Does lower limb amputation concern all SGLT2 inhibitors? The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review. Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both? SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice Renal Outcomes of Antidiabetic Treatment Options for Type 2 Diabetes-A Proposed MARE Definition Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough? New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes Canagliflozin should be prescribed with caution to individuals with type 2 diabetes and high risk of amputation The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors. Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions Cardioprotective diabetes drugs: what cardiologists need to know Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects Canagliflozin impairs blood reperfusion of ischaemic lower limb partially by inhibiting the retention and paracrine function of bone marrow derived mesenchymal stem cells Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight, and blood pressure reduction in the real world
is cites work of	wds:Q40081685-2A1D5FDB-1AA1-44B2-9B36-70B1CB9BDE11 wds:Q47652080-09293775-0E54-4C39-ACF7-59265586BDFD wds:Q59330606-8B7D90F7-DFC7-413E-80AA-6251B3CC3631 wds:Q60045997-F5B8B540-593C-42CA-B2E8-07C9F76CFCF6 wds:Q64091931-89E05500-CCB3-4FFC-A8D9-B74BA6FB5375 wds:Q88295526-708C0013-9955-447D-8DFC-DBBFC6078B89 wds:Q51733588-0E070FD5-E5CF-43C6-81E8-73B7847A977C wds:Q57025347-E6265419-B967-4253-A136-082C7139ADA7 wds:Q64355352-E46819AD-9165-4A6B-B857-E5AC940B2E9E wds:Q49955687-2DD10218-E292-492E-885F-1E2FDBE78805 wds:Q50042476-CB347D7D-7E4F-450A-8B60-C20888E9D70E wds:Q90433933-7ABD8337-C848-4D78-A430-AD1035EDBCB5 wds:Q88086293-8374FE10-A73F-47A2-B1EE-5B7443AD05AF wds:Q57179232-04B9EF1C-3AF6-41F3-8A8F-BAF3666FB69E wds:Q64916602-4C5E63B4-1728-4658-8B7D-42B005ABB834 wds:Q92940317-EB393F02-5D8D-4E69-845F-BDDC246FED33 wds:Q92184218-9052F6B8-798E-4A05-84E6-17554516DB44 wds:Q47614541-EFC2CA92-F96B-4D16-BBC9-9D1D3C0CE821 wds:Q48113639-9705BACB-AF6B-4E7B-94EF-5FFF9062CA6F wds:Q56365917-AC2F03D1-0077-4121-B6A9-5598526E2638 wds:Q92703271-A22A86E3-37D4-4E7C-BD2E-D4985129BD05

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software